In a report released today, Kostas Biliouris from BMO Capital maintained a Hold rating on Precision BioSciences (DTIL – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $0.53. According to TipRanks, Biliouris is an analyst with an average return of -1.7% and a 35.48% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Ionis Pharmaceuticals. Currently, the analyst consensus on Precision BioSciences is a Strong Buy with an average price target of $2.88. See Insiders’ Hot Stocks on TipRanks >>  The company has a one-year high of $1.98  and a one-year low of $0.47. Currently, Precision BioSciences has an average volume of 972.6K.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.  Read More on DTIL: Indices Commodities Currencies Stocks